Menu Search
Equities

Valeo Pharma Inc

VP2:BER

Valeo Pharma Inc

Actions
  • Price (EUR)0.0445
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-73.82%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 19:48 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CADIncome statement in CADView more

Year on year Valeo Pharma Inc had net income fall 8.01% from a loss of 25.75m to a larger loss of 27.81m despite revenues that grew 94.31% from 27.75m to 53.91m over the same period.
Gross margin16.51%
Net profit margin-60.18%
Operating margin-37.50%
Return on assets-82.64%
Return on equity--
Return on investment--
More ▼

Cash flow in CADView more

In 2023, cash reserves at Valeo Pharma Inc fell by 15.00m. Cash Flow from Financing totalled 6.19m or 11.48% of revenues. In addition the company used 15.70m for operations while cash used for investing totalled 5.55m.
Cash flow per share-0.3128
Price/Cash flow per share--
Book value per share-0.6388
Tangible book value per share-0.7469
More ▼

Balance sheet in CADView more

Valeo Pharma Inc appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load is greater than its assets while day-to-day operations are losing money.
Current ratio0.2726
Quick ratio0.202
Total debt/total equity--
Total debt/total capital9.94
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.